Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins

Camilo Ayala-Breton, Glen N Barber, Stephen J. Russell, Kah Whye Peng

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Oncolytic vesicular stomatitis virus (VSV) has potent antitumor activity, but infects a broad range of cell types. Here, we used the measles virus (MV) hemagglutinin (H) and fusion (F) envelope glycoproteins to redirect VSV entry and infection specifically to tumor-associated receptors. Replication-defective VSV, deleted of its glycoprotein gene (VSVΔG), was pseudotyped with MV-F and MV-H displaying single-chain antibodies (scFv) specific for epidermal growth factor receptor (EGFR), folate receptor (FR), or prostate membrane-specific antigen (PSMA). Viral titers were ∼105 PFU/ml, but could be concentrated to 107 PFU/ml. Immunoblotting confirmed incorporation of the MV-H-scFv and MV-F into functional VSV virions. Although VSV-G was able to infect all tumor cell lines tested, the retargeted VSV infected only cells that expressed the targeted receptor. In vivo specificities of the EGFR-, FR-, and PSMA-retargeted VSV were assessed by intratumoral injection into human tumor xenografts. Analysis of green fluorescent protein reporter gene expression indicated that VSV infection was restricted to receptor-positive tumors. In summary, we have demonstrated for the first time that VSV can be efficiently retargeted to different cellular receptors using the measles display technology, yielding retargeted VSV vectors that are highly specific for tumors that express the relevant receptor.

Original languageEnglish
Pages (from-to)484-491
Number of pages8
JournalHuman Gene Therapy
Volume23
Issue number5
DOIs
StatePublished - May 1 2012

Fingerprint

Measles virus
Vesicular Stomatitis
Glycoproteins
Viruses
Virus Diseases
Folic Acid
Epidermal Growth Factor Receptor
Neoplasms
Single-Chain Antibodies
Virus Internalization
Measles
Hemagglutinins
Green Fluorescent Proteins
Tumor Cell Line
Reporter Genes
Immunoblotting
Heterografts
Virion
Technology
Gene Expression

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. / Ayala-Breton, Camilo; Barber, Glen N; Russell, Stephen J.; Peng, Kah Whye.

In: Human Gene Therapy, Vol. 23, No. 5, 01.05.2012, p. 484-491.

Research output: Contribution to journalArticle

Ayala-Breton, Camilo ; Barber, Glen N ; Russell, Stephen J. ; Peng, Kah Whye. / Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. In: Human Gene Therapy. 2012 ; Vol. 23, No. 5. pp. 484-491.
@article{db765271b08a42a08176c9881818aba1,
title = "Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins",
abstract = "Oncolytic vesicular stomatitis virus (VSV) has potent antitumor activity, but infects a broad range of cell types. Here, we used the measles virus (MV) hemagglutinin (H) and fusion (F) envelope glycoproteins to redirect VSV entry and infection specifically to tumor-associated receptors. Replication-defective VSV, deleted of its glycoprotein gene (VSVΔG), was pseudotyped with MV-F and MV-H displaying single-chain antibodies (scFv) specific for epidermal growth factor receptor (EGFR), folate receptor (FR), or prostate membrane-specific antigen (PSMA). Viral titers were ∼105 PFU/ml, but could be concentrated to 107 PFU/ml. Immunoblotting confirmed incorporation of the MV-H-scFv and MV-F into functional VSV virions. Although VSV-G was able to infect all tumor cell lines tested, the retargeted VSV infected only cells that expressed the targeted receptor. In vivo specificities of the EGFR-, FR-, and PSMA-retargeted VSV were assessed by intratumoral injection into human tumor xenografts. Analysis of green fluorescent protein reporter gene expression indicated that VSV infection was restricted to receptor-positive tumors. In summary, we have demonstrated for the first time that VSV can be efficiently retargeted to different cellular receptors using the measles display technology, yielding retargeted VSV vectors that are highly specific for tumors that express the relevant receptor.",
author = "Camilo Ayala-Breton and Barber, {Glen N} and Russell, {Stephen J.} and Peng, {Kah Whye}",
year = "2012",
month = "5",
day = "1",
doi = "10.1089/hum.2011.146",
language = "English",
volume = "23",
pages = "484--491",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins

AU - Ayala-Breton, Camilo

AU - Barber, Glen N

AU - Russell, Stephen J.

AU - Peng, Kah Whye

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Oncolytic vesicular stomatitis virus (VSV) has potent antitumor activity, but infects a broad range of cell types. Here, we used the measles virus (MV) hemagglutinin (H) and fusion (F) envelope glycoproteins to redirect VSV entry and infection specifically to tumor-associated receptors. Replication-defective VSV, deleted of its glycoprotein gene (VSVΔG), was pseudotyped with MV-F and MV-H displaying single-chain antibodies (scFv) specific for epidermal growth factor receptor (EGFR), folate receptor (FR), or prostate membrane-specific antigen (PSMA). Viral titers were ∼105 PFU/ml, but could be concentrated to 107 PFU/ml. Immunoblotting confirmed incorporation of the MV-H-scFv and MV-F into functional VSV virions. Although VSV-G was able to infect all tumor cell lines tested, the retargeted VSV infected only cells that expressed the targeted receptor. In vivo specificities of the EGFR-, FR-, and PSMA-retargeted VSV were assessed by intratumoral injection into human tumor xenografts. Analysis of green fluorescent protein reporter gene expression indicated that VSV infection was restricted to receptor-positive tumors. In summary, we have demonstrated for the first time that VSV can be efficiently retargeted to different cellular receptors using the measles display technology, yielding retargeted VSV vectors that are highly specific for tumors that express the relevant receptor.

AB - Oncolytic vesicular stomatitis virus (VSV) has potent antitumor activity, but infects a broad range of cell types. Here, we used the measles virus (MV) hemagglutinin (H) and fusion (F) envelope glycoproteins to redirect VSV entry and infection specifically to tumor-associated receptors. Replication-defective VSV, deleted of its glycoprotein gene (VSVΔG), was pseudotyped with MV-F and MV-H displaying single-chain antibodies (scFv) specific for epidermal growth factor receptor (EGFR), folate receptor (FR), or prostate membrane-specific antigen (PSMA). Viral titers were ∼105 PFU/ml, but could be concentrated to 107 PFU/ml. Immunoblotting confirmed incorporation of the MV-H-scFv and MV-F into functional VSV virions. Although VSV-G was able to infect all tumor cell lines tested, the retargeted VSV infected only cells that expressed the targeted receptor. In vivo specificities of the EGFR-, FR-, and PSMA-retargeted VSV were assessed by intratumoral injection into human tumor xenografts. Analysis of green fluorescent protein reporter gene expression indicated that VSV infection was restricted to receptor-positive tumors. In summary, we have demonstrated for the first time that VSV can be efficiently retargeted to different cellular receptors using the measles display technology, yielding retargeted VSV vectors that are highly specific for tumors that express the relevant receptor.

UR - http://www.scopus.com/inward/record.url?scp=84861690462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861690462&partnerID=8YFLogxK

U2 - 10.1089/hum.2011.146

DO - 10.1089/hum.2011.146

M3 - Article

VL - 23

SP - 484

EP - 491

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 5

ER -